Related references
Note: Only part of the references are listed.Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis
Lenka Novakova et al.
JOURNAL OF NEUROCHEMISTRY (2017)
Imaging as an Outcome Measure in Multiple Sclerosis
Daniel Ontaneda et al.
NEUROTHERAPEUTICS (2017)
Serum neurofilament is associated with progression of brain atrophy and disability in early MS
Jens Kuhle et al.
NEUROLOGY (2017)
Blood-based NfL A biomarker for differential diagnosis of parkinsonian disorder
Oskar Hansson et al.
NEUROLOGY (2017)
Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
Jens Kuhle et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE
C. Alvarez-Gonzalez et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
Jens Kuhle et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
Jonathan D. Rohrer et al.
NEUROLOGY (2016)
Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases
Mehtap Bacioglu et al.
NEURON (2016)
Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression
Henrik Zetterberg et al.
JAMA NEUROLOGY (2016)
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
Jens Kuhle et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Plasma neurofilament light chain predicts progression in progressive supranuclear palsy
Julio C. Rojas et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
Magnus Gisslen et al.
EBIOMEDICINE (2016)
Serum neurofilament light protein predicts clinical outcome in traumatic brain injury
Pashtun Shahim et al.
SCIENTIFIC REPORTS (2016)
Exploring the origins of grey matter damage in multiple sclerosis
Massimiliano Calabrese et al.
NATURE REVIEWS NEUROSCIENCE (2015)
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
Jens Kuhle et al.
NEUROLOGY (2015)
Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction
Mattias Vagberg et al.
PLOS ONE (2015)
Body fluid biomarkers in multiple sclerosis
Manuel Comabella et al.
LANCET NEUROLOGY (2014)
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
Markus Axelsson et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Natalizumab in progressive MS Results of an open-label, phase 2A, proof-of-concept trial
Jeppe Romme Christensen et al.
NEUROLOGY (2014)
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis
J. Kuhle et al.
ACTA NEUROLOGICA SCANDINAVICA (2013)
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Maria Pia Sormani et al.
LANCET NEUROLOGY (2013)
A comparative study of CSF neurofilament light and heavy chain protein in MS
Jens Kuhle et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers
Mohsen Khademi et al.
PLOS ONE (2013)
Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS - Neurofilament as a Surrogate of Disease Progression
Sharmilee Gnanapavan et al.
PLOS ONE (2013)
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
Johanna Gaiottino et al.
PLOS ONE (2013)
Neurofilaments as biomarkers in multiple sclerosis
Charlotte E. Teunissen et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
Martin Gunnarsson et al.
ANNALS OF NEUROLOGY (2011)
Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis
Emma C. Tallantyre et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Share Paper
